Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
500
Views
6
CrossRef citations to date
0
Altmetric
Author's View

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients

Hojabr Kakavand Melanoma Institute Australia; North Sydney, NSW Australia; The University of Sydney; Sydney, NSW Australia
,
Richard A Scolyer Melanoma Institute Australia; North Sydney, NSW Australia; The University of Sydney; Sydney, NSW Australia; Tissue Pathology and Diagnostic Oncology; Royal Prince Alfred Hospital; Camperdown, NSW Australia
,
John F Thompson Melanoma Institute Australia; North Sydney, NSW Australia; The University of Sydney; Sydney, NSW Australia; Department of Melanoma and Surgical Oncology; Royal Prince Alfred Hospital; Camperdown, NSW AustraliaCorrespondence[email protected]
&
Graham J Mann Melanoma Institute Australia; North Sydney, NSW Australia; The University of Sydney; Sydney, NSW Australia; Westmead Millennium Institute; Westmead, NSW Australia
Article: e25564 | Received 25 Jun 2013, Accepted 27 Jun 2013, Published online: 03 Jul 2013

References

  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694 - 703; http://dx.doi.org/10.1056/NEJMoa1210093; PMID: 23020132
  • Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127
  • Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199 - 206; http://dx.doi.org/10.1200/JCO.2009.23.4799; PMID: 19917835
  • Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm S-J, Pianova S, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013; 133:509 - 17; http://dx.doi.org/10.1038/jid.2012.283; PMID: 22931913
  • Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012; 13:589 - 97; http://dx.doi.org/10.1016/S1470-2045(12)70138-9; PMID: 22575589
  • Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30:2678 - 83; http://dx.doi.org/10.1200/JCO.2011.37.8539; PMID: 22711850
  • Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925 - 31; http://dx.doi.org/10.1056/NEJMoa1112824; PMID: 22397654

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.